High-Dose Chemotherapy and Breast Cancer . . . One More Time!
This clinical trial, as well as those that preceded it, has failed to identify a group of breast cancer patients for whom high-dose chemotherapy confers a significant advantage over non–marrow-ablative chemotherapy approaches.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)